An interventional study of Walking in Multiple Sclerosis, sponsored by Rutgers, The State University of New Jersey. Suspended at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-12.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Treatment
This study will compare the effectiveness of a traditional, continuous walking rehabilitation program for people with MS to the novel intervention of an intermittent or interval walking rehabilitation program. Half of the participants will receive the continuous walking program while the other half will receive the novel intermittent walking program.
The typical rehabilitation of walking difficulties for people with MS has included practice walking. In general, this includes training to build walking endurance by having the person with MS walk until he/she becomes tired and needs to stop. Although this model has been used successfully to treat people with other diagnoses, it has limited effectiveness in improving walking ability and endurance in people with MS because of fatigue. Recently, a different model has been considered: intermittent or interval walking training. Interval walking training is organized such that seated rest breaks are intentionally interspersed between walking training bouts that end before the person with MS becomes too tired to continue. Exploratory research has shown that people with MS can walk faster and farther when using interval walking training, and may have more improvements in walking ability and endurance after using interval walking training. This study will compare the effectiveness of the traditional model of continuous walking training to the promising new model of interval walking training. This will help to determine whether interval or continuous walking training is superior in improving walking ability and endurance in people with MS.
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's planned enrollment of 24 is below the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Rutgers, The State University of New Jersey is the lead sponsor of 496 studies on the registry; 130 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 30 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks
Other: Walking
Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk
Other: Walking
Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
Change in 6-minute Walk Test distance
Is a measurement of the distance (in meters) walked at best pace in six minutes.
Time frame: Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up)
Change in 12-item Multiple Sclerosis Walking Scale score
A survey that measures a participant's perception of how his/her walking ability is affected by multiple sclerosis. The scale ranges from 0-100 with lower scores representing a lesser impact of multiple sclerosis on the participant's walking ability. There are no subscales.
Time frame: Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up)
Change in Fatigue Severity Scale score
A survey that measures a participant's perception of the impact of the symptom of fatigue on a person's ability to participate in life roles. The scale ranges from from 9-63, with lower scores representing a lower impact of fatigue on the ability to perform the activities listed in the scale.There are no subscales.
Time frame: Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up)
Change in Step Length
The distance (in centimeters) traversed in one step from initial contact of one foot to the initial contact of the opposite foot.
Time frame: Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up)
Change in Step Time
The time (in seconds) taken to complete one step from initial contact of one foot to the initial contact of the opposite foot.
Time frame: Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up)
Change in Stride Velocity
The speed with which it takes a person to complete one stride from initial contact of one foot to the next initial contact of the same foot
Time frame: Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up)
Change in Cadence
The number of steps (the initial contact of one foot to the initial contact of the opposite foot taken per minute
Time frame: Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up)
Plan to share: No
No publications or documents are linked to this record.
This study is suspended, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey